Novartis new analysis shows high consistency in lowering LDL-C in individual response with investigational inclisiran
The Pharma Data
AUGUST 29, 2020
Pooled data from Phase III ORION-10 and -11 showed highly consistent efficacy, tolerability and safety profile over 17 months on twice-yearly subcutaneous dosing in 2,300 patients (of which 1,164 were on inclisiran) 1 . New post-hoc analysis demonstrates 99% of patients treated with inclisiran showed placebo-adjusted reduction in low-density lipoprotein cholesterol (LDL-C) of ?
Let's personalize your content